Dr. Pierre St-Michel obtained his Medical Degree from the University of Montreal in 1976 and completed his training specializing in obstetrics-gynecology at the same institution in 1980. He was a recipient of a Medical Research Council of Canada Scholarship; Dr. St-Michel has been licensed to practice medicine in California since 1980. He completed his fellowship studies in reproductive endocrinology and infertility at the University of Southern California (USC) in 1981. Dr. St-Michel is certified by the Royal College of Physicians and Surgeons of Canada as a specialist in obstetrics-gynecology and is a member of the Quebec College of Physicians. He is also certified by the Medical Council of Canada and by the National Board of Medical Examiners (U.S.). Dr. St-Michel was Chief of Surgery at Hôpital Fleury in Montreal from 1998 to 2002. He was also a member of the Board of Administrators of the same hospital in 2002. He joined the Company’s Montreal operations in 1995.

In addition to his clinical duties, Dr. St-Michel has been President and Chief Executive Officer of the Company since December 2002. He is currently one of the medical directors of the ART Medical Board Canadian Fertility and Andrology Society. He is an active member of the Canadian Fertility and Andrology Society and the American Society of Reproductive and Capital Medicine. From 1982 to 1985 Dr. St-Michel was on the Board of Directors and a principal shareholder of “Les Ordinateurs Hypocrat” which made an initial public offering of its shares in 1982 and a second public offering in 1984-1985. That company was listed on the Montreal stock exchange and was sold to an American public company in 1995.

From 1984 to 1987, Dr. St-Michel was a member of the Board of Directors of Domicil Inc. which went public in 1984-1985. That company was listed on the Montreal stock exchange and Dr. St-Michel was one of its principal stockholders, financial vice-president and secretary of the company. Dr. St-Michel was involved in the pre-capitalization of various private companies and the amalgamation of such companies before their first public offering.